Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation.
Comprehensive Psychoneuroendocrinology February 1, 2023 Daniel Rødbro Burmester, Martin Korsbak Madsen, Attila Szabo et al. 24 citations
Psilocybin is a serotonergic psychedelic that has gained prominent attention recently as a potential therapeutic for neuropsychiatric disorders including Major Depressive Disorder. Pre-clinical and initial studies in humans suggest that serotonin 2A receptor agonists, including serotonergic psychedelics, have anti-inflammatory effects. This may contribute to its therapeutic effects as previous...
DOI: 10.1016/j.cpnec.2022.100163 (opens in new tab)
Full text (opens in new tab)
Psychedelic mushrooms
Immune system
Neuroinflammation
Psychedelics
+7